Jpmorgan Chase & CO Immuneering Corp Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Immuneering Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,974 shares of IMRX stock, worth $3,671. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,974

Previous 9,289 78.75%

Holding current value

$3,671

Previous $26,000 92.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.28 - $2.75 $9,363 - $20,116	-7,315 Reduced 78.75%	1,974 $2,000
Q1 2024 May 10, 2024	SELL	$1.91 - $7.32 $12,959 - $49,666	-6,785 Reduced 42.21%	9,289 $26,000
Q4 2023 Feb 12, 2024	SELL	$4.84 - $8.44 $20,739 - $36,165	-4,285 Reduced 21.05%	16,074 $118,000
Q3 2023 Nov 14, 2023	BUY	$7.21 - $10.68 $25,790 - $38,202	3,577 Added 21.31%	20,359 $156,000
Q2 2023 Aug 11, 2023	BUY	$6.49 - $13.36 $102,230 - $210,446	15,752 Added 1529.32%	16,782 $170,000
Q1 2023 May 11, 2023	BUY	$3.78 - $10.38 $264 - $726	70 Added 7.29%	1,030 $10,000
Q4 2022 Feb 13, 2023	SELL	$4.09 - $15.0 $748 - $2,745	-183 Reduced 16.01%	960 $5,000
Q3 2022 Nov 14, 2022	BUY	$5.0 - $14.32 $50 - $143	10 Added 0.88%	1,143 $16,000
Q2 2022 Aug 11, 2022	SELL	$3.89 - $7.81 $42,152 - $84,629	-10,836 Reduced 90.53%	1,133 $6,000
Q1 2022 May 11, 2022	BUY	$6.47 - $16.99 $42,152 - $110,689	6,515 Added 119.45%	11,969 $78,000
Q4 2021 Feb 10, 2022	BUY	$16.12 - $31.02 $36,866 - $70,942	2,287 Added 72.21%	5,454 $88,000
Q3 2021 Nov 12, 2021	BUY	$17.0 - $32.84 $53,839 - $104,004	3,167 New	3,167 $84,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

9.63M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $49.1M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Immuneering Corp Transaction History